Orforglipron, an oral GLP-1 medication, has been approved for obesity. The medication, also known as Foundayo, has been studied in clinical trials for its effectiveness in weight loss and maintenance. Reports suggest it may offer flexible dosing without food or water restrictions, but details about its use and potential impact on the market are still emerging.